Revenue
2022
2023
2024
2025
Tyra Biosciences, Inc. (TYRA)
Price$28.65Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $102.9M | $80.1M | $62.5M | $43.0M | $20.6M | $7.2M |
| Operating expenses | $132.8M | $104.2M | $79.9M | $58.9M | $26.3M | $9.3M |
| Operating income | −$132.8M | −$104.2M | −$79.9M | −$58.9M | −$26.3M | −$9.3M |
| EBITDA | −$132.2M | −$103.7M | −$79.6M | −$58.6M | −$26.1M | −$9.3M |
| Net income | −$119.9M | −$86.5M | −$69.1M | −$55.3M | −$26.3M | −$9.3M |
| Basic EPSper basic share | -$2.01 | -$1.51 | -$1.62 | -$1.32 | -$1.91 | -$6.05 |
| Diluted EPSper diluted share | -$2.01 | -$1.51 | -$1.62 | -$1.32 | -$1.91 | -$6.05 |
Owners
Reported shareholders
20.45%of listed shares
RA CAPITAL MANAGEMENT, L.P.12.2M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 20.45%12.2M shares |
FMR LLC | 14.95%8.92M shares |
Boxer Capital Management, LLC | ≈7.46%4.45M shares |
Jupiter Topco LLC | 7.30%4.35M shares |
Kjellson Nina S | ≈6.95%4.14M shares |
MORE ROBERT J | ≈6.41%3.82M shares |
Alta Partners Management Company, L.P. | 6.41%3.82M shares |
Nextech Invest Ltd. | 5.96%3.55M shares |
TCG Crossover Management, LLC | 5.45%3.25M shares |
BlackRock, Inc. | 5.08%3.03M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 4.66%2.78M shares |
STATE STREET CORP | 3.59%2.14M shares |
Commodore Capital LP | 3.14%1.88M shares |
Paradigm Biocapital Advisors LP | 3.06%1.83M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.53%1.51M shares |
BVF INC/IL | 2.47%1.48M shares |
Harris Todd | ≈2.41%1.44M shares |
5AM Venture Management, LLC | 1.73%1.03M shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 1.70%1.02M shares |
Hood River Capital Management LLC | 1.70%1.02M shares |
Percentages use 59.66M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 25, 2026Form 4 | KAPLAN GILLADirector | SellCommon Stock | 14.3K | $36.97 | $528.5K | 28.2K |
| Feb 12, 2026Form 4 · 10b5-1 | Bensen DanielChief Discovery Officer | SellCommon Stock | 5.9K | $33.37 | $195.9K | 147.0K |
| Feb 12, 2026Form 4 · 10b5-1 | Bensen DanielChief Discovery Officer | SellCommon Stock | 2.1K | $31.50 | $67.0K | 152.9K |
| Jan 12, 2026Form 4 · 10b5-1 | Bensen DanielChief Discovery Officer | SellCommon Stock | 1.0K | $29.08 | $29.6K | 155.0K |
| Jan 12, 2026Form 4 · 10b5-1 | Bensen DanielChief Discovery Officer | SellCommon Stock | 7.0K | $28.44 | $198.6K | 156.0K |
Community posts
Tyra prices $400 million financing to support drug development
Tyra Biosciences ($TYRA) priced an underwritten financing expected to raise approximately $400 million before fees and expenses. The transaction comprises 9,079,000 common shares at $22.03 each and pre-funded warrants covering another 9,078 ...
